| scholarly article | Q13442814 |
| P356 | DOI | 10.3945/AJCN.2009.27981 |
| P8608 | Fatcat ID | release_6jnpfxjfengjnntyb5if4zwkue |
| P932 | PMC publication ID | 2744624 |
| P698 | PubMed publication ID | 19710188 |
| P5875 | ResearchGate publication ID | 26770172 |
| P2093 | author name string | Xueheng Zhao | |
| James E Heubi | |||
| Pinky Jha | |||
| Nadine M Brown | |||
| Kenneth Dr Setchell | |||
| P2860 | cites work | The identification of the weak oestrogen equol [7-hydroxy-3-(4'-hydroxyphenyl)chroman] in human urine | Q24531190 |
| Enantioselective synthesis of S-equol from dihydrodaidzein by a newly isolated anaerobic human intestinal bacterium | Q24557533 | ||
| Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equol production by the gut microflora | Q28143631 | ||
| Interaction of phytoestrogens with estrogen receptors alpha and beta | Q28212740 | ||
| Gut bacterial metabolism of the soy isoflavone daidzein: exploring the relevance to human health | Q28236996 | ||
| Method of defining equol-producer status and its frequency among vegetarians | Q28253168 | ||
| Urinary equol excretion with a soy challenge: influence of habitual diet | Q28264036 | ||
| Soymilk or progesterone for prevention of bone loss--a 2 year randomized, placebo-controlled trial | Q33205929 | ||
| Liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of estradiol and estrone in human plasma | Q33430674 | ||
| The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones | Q34162974 | ||
| Nonsteroidal estrogens of dietary origin: possible roles in hormone-dependent disease | Q34258149 | ||
| S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora | Q34417374 | ||
| Variations in phytoestrogen content between different mill dates of the same diet produces significant differences in the time of vaginal opening in CD-1 mice and F344 rats but not in CD Sprague-Dawley rats | Q36264552 | ||
| Estimated Asian adult soy protein and isoflavone intakes | Q36590662 | ||
| Animal models impacted by phytoestrogens in commercial chow: implications for pathways influenced by hormones | Q43606362 | ||
| Metabolism of the soybean isoflavone glycoside genistin in vitro by human gut bacteria and the effect of prebiotics | Q44586040 | ||
| Phytoestrogens modulate binding response of estrogen receptors alpha and beta to the estrogen response element | Q44685845 | ||
| Equol is a novel anti-androgen that inhibits prostate growth and hormone feedback | Q44697356 | ||
| Dietary phytoestrogens accelerate the time of vaginal opening in immature CD-1 mice. | Q44731546 | ||
| Equol, a natural estrogenic metabolite from soy isoflavones: convenient preparation and resolution of R- and S-equols and their differing binding and biological activity through estrogen receptors alpha and beta | Q44798276 | ||
| Consumption of Lactobacillus acidophilus and Bifidobacterium longum do not alter urinary equol excretion and plasma reproductive hormones in premenopausal women | Q44949327 | ||
| Lactobacillus gasseri: effects on mouse intestinal flora enzyme activity and isoflavonoids in the caecum and plasma | Q45143871 | ||
| Isolation and identification of equol-producing bacterial strains from cultures of pig faeces | Q45357436 | ||
| Acute and subchronic toxicity and genotoxicity of SE5-OH, an equol-rich product produced by Lactococcus garvieae | Q46539586 | ||
| Microbial and dietary factors are associated with the equol producer phenotype in healthy postmenopausal women | Q49043125 | ||
| Administration of equol-producing bacteria alters the equol production status in the Simulator of the Gastrointestinal Microbial Ecosystem (SHIME). | Q49088621 | ||
| Decreased serum total cholesterol concentration is associated with high intake of soy products in Japanese men and women. | Q50627921 | ||
| Metabolic phenotype of isoflavones differ among female rats, pigs, monkeys, and women. | Q51810532 | ||
| Soya--a dietary source of the non-steroidal oestrogen equol in man and animals. | Q53805250 | ||
| Steroid and phyto-oestrogen binding to sheep uterine receptors in vitro | Q70342780 | ||
| Affinity of rabbit uterine oestradiol receptor for phyto-oestrogens and its use in a competitive protein-binding radioassay for plasma coumestrol | Q70346583 | ||
| Conjugation of Lignans in human urine | Q72886777 | ||
| Bioavailability, disposition, and dose-response effects of soy isoflavones when consumed by healthy women at physiologically typical dietary intakes | Q73209056 | ||
| Analysis of soy isoflavone conjugation in vitro and in human blood using liquid chromatography-mass spectrometry | Q73462668 | ||
| Bioavailability of soybean isoflavones from aglycone and glucoside forms in American women | Q73490346 | ||
| Wheat bran and soy protein feeding do not alter urinary excretion of the isoflavan equol in premenopausal women | Q73587217 | ||
| Estrogenic activity of some isoflavone derivatives | Q73631798 | ||
| Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements | Q73707852 | ||
| Soy isoflavone aglycones are absorbed faster and in higher amounts than their glucosides in humans | Q73924402 | ||
| Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability | Q74529751 | ||
| Plasma and urinary kinetics of the isoflavones daidzein and genistein after a single soy meal in humans | Q74535186 | ||
| Pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein in men and women after consumption of a soy beverage | Q74666546 | ||
| Antioxidant activities of isoflavones and their biological metabolites in a liposomal system | Q77094970 | ||
| Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men | Q77386775 | ||
| Usual dietary consumption of soy foods and its correlation with the excretion rate of isoflavonoids in overnight urine samples among Chinese women in Shanghai | Q77396515 | ||
| Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver beta-glucosidase activity | Q77408444 | ||
| Antioxidant efficacy of phytoestrogens in chemical and biological model systems | Q77593106 | ||
| Dietary intake and sources of isoflavones among Japanese | Q77881860 | ||
| Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women | Q78424847 | ||
| Comparing the pharmacokinetics of daidzein and genistein with the use of 13C-labeled tracers in premenopausal women | Q78829975 | ||
| Sulfation of the isoflavones genistein and daidzein in human and rat liver and gastrointestinal tract | Q79147472 | ||
| Production of phytoestrogen S-equol from daidzein in mixed culture of two anaerobic bacteria | Q79364064 | ||
| Plasma phytoestrogens are not altered by probiotic consumption in postmenopausal women with and without a history of breast cancer | Q80397108 | ||
| Increased probiotic yogurt or resistant starch intake does not affect isoflavone bioavailability in subjects consuming a high soy diet | Q80682248 | ||
| Influence of inulin on plasma isoflavone concentrations in healthy postmenopausal women | Q81153063 | ||
| Chemical synthesis of [(13)c]daidzein | Q83466872 | ||
| P4510 | describes a project that uses | stable isotope | Q878130 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| stable isotope | Q878130 | ||
| P304 | page(s) | 1029-37 | |
| P577 | publication date | 2009-10-01 | |
| P1433 | published in | American Journal of Clinical Nutrition | Q7713500 |
| P1476 | title | The pharmacokinetic behavior of the soy isoflavone metabolite S-(-)equol and its diastereoisomer R-(+)equol in healthy adults determined by using stable-isotope-labeled tracers | |
| P478 | volume | 90 |
| Q35914108 | Acute benefits of the microbial-derived isoflavone metabolite equol on arterial stiffness in men prospectively recruited according to equol producer phenotype: a double-blind randomized controlled trial. |
| Q35643914 | Analysis of urinary estrogens, their oxidized metabolites, and other endogenous steroids by benchtop orbitrap LCMS versus traditional quadrupole GCMS. |
| Q39032494 | Calcium-41: a technology for monitoring changes in bone mineral |
| Q33908755 | Cautions and research needs identified at the equol, soy, and menopause research leadership conference |
| Q64059737 | Characterization and bioactivity of self-assembled anti-angiogenic chondroitin sulfate-ES2-AF nanoparticle conjugate |
| Q35670918 | Comparative effects of R- and S-equol and implication of transactivation functions (AF-1 and AF-2) in estrogen receptor-induced transcriptional activity. |
| Q38663475 | Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis. |
| Q36235285 | Endogenous and exogenous equol are antiestrogenic in reproductive tissues of apolipoprotein e-null mice |
| Q36655771 | Equol inhibits growth, induces atresia, and inhibits steroidogenesis of mouse antral follicles in vitro |
| Q37512708 | Equol production changes over time in postmenopausal women |
| Q29248888 | Equol, a Dietary Daidzein Gut Metabolite Attenuates Microglial Activation and Potentiates Neuroprotection In Vitro |
| Q33908748 | Equol, via dietary sources or intestinal production, may ameliorate estrogen deficiency-induced bone loss |
| Q24594674 | Equol: history, chemistry, and formation |
| Q24594626 | Equol: pharmacokinetics and biological actions |
| Q35048199 | Estrogen receptor and PI3K/Akt signaling pathway involvement in S-(-)equol-induced activation of Nrf2/ARE in endothelial cells |
| Q35992562 | Impact of equol-producing capacity and soy-isoflavone profiles of supplements on bone calcium retention in postmenopausal women: a randomized crossover trial |
| Q35234941 | Impact of perinatal exposure to equol enantiomers on reproductive development in rodents |
| Q42944121 | Mammary gland differentiation by early life exposure to enantiomers of the soy isoflavone metabolite equol |
| Q30841046 | Pharmaco- and toxicokinetics of selected exogenous and endogenous estrogens: a review of the data and identification of knowledge gaps |
| Q48106159 | Pharmacokinetics and safety profile of single-dose administration of an estrogen receptor β-selective phytoestrogenic (phytoSERM) formulation in perimenopausal and postmenopausal women |
| Q37697453 | Pharmacokinetics of equol, a soy isoflavone metabolite, changes with the form of equol (dietary versus intestinal production) in ovariectomized rats |
| Q36993533 | Possible role of S-equol on bone loss via amelioration of inflammatory indices in ovariectomized mice |
| Q36902122 | Potentiation of brain mitochondrial function by S-equol and R/S-equol estrogen receptor β-selective phytoSERM treatments |
| Q38314044 | Protective effects of equol and their polyphenolic isomers against dermal aging: microarray/protein evidence with clinical implications and unique delivery into human skin |
| Q61817344 | Screening dietary biochanin A, daidzein, equol and genistein for their potential to increase DHA biosynthesis in rainbow trout (Oncorhynchus mykiss) |
| Q35335557 | Soy isoflavone phase II metabolism differs between rodents and humans: implications for the effect on breast cancer risk |
| Q24628910 | The chemopreventive action of equol enantiomers in a chemically induced animal model of breast cancer |
| Q34005314 | The metabolism and analysis of isoflavones and other dietary polyphenols in foods and biological systems |
| Q47442621 | The phytoestrogens daidzein and equol inhibit the drug transporter BCRP/ABCG2 in breast cancer cells: potential chemosensitizing effect |
Search more.